Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
NewCo’s pipeline includes five investigational medicines
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Singhal brings a powerful blend of operational excellence, investor acumen, and visionary thinking
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Subscribe To Our Newsletter & Stay Updated